Focus on research: Drugs and valvular heart disease

New England Journal of Medicine

Volumn 356, Issue 1, 2007, Pages 6-9

  Roth, Bryan L ^a,b  

^a Schools of Medicine and Pharmacy

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR; BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; DIHYDROERGOTAMINE; ERGOTAMINE; FENFLURAMINE; LISURIDE; METHYLERGOMETRINE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROLEPTIC AGENT; NORFENFLURAMINE; PERGOLIDE; PRAMIPEXOLE; PROTEIN TYROSINE KINASE; RETINA S ANTIGEN; ROXINDOLE; SEROTONIN RECEPTOR; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; SEROTONIN 2B RECEPTOR; SEROTONIN AGONIST;

AORTA VALVE; DRUG MECHANISM; ECHOGRAPHY; HUMAN; MITOGENESIS; MITRAL VALVE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRICUSPID VALVE; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; METABOLISM; NOTE;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; ERGOLINES; HEART VALVE DISEASES; HUMANS; PERGOLIDE; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN AGONISTS;

EID: 33846017361     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/nejmp068265     Document Type: Review

References (5)

1. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
2. Devereux RB. Appetite suppressants and valvular heart disease. N Engl J Med 1998;339:765-6.
3. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
4. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003;63:1223-9.
5. Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fenphen.' Expert Opin Drug Metab Toxicol 2005;1:377-87.